PROCEPT BioRobotics/PRCT

$50.86

-0.43%
-
1D1W1MYTD1YMAX

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Ticker

PRCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Reza Zadno

Employees

626

Headquarters

San jose, United States

PRCT Metrics

BasicAdvanced
$2.64B
Market cap
-
P/E ratio
-$2.24
EPS
-
Beta
-
Dividend rate
$2.64B
$54.50
$24.83
462.54K
7.633
6.768
18.286
18.286
-29.66%
-44.32%
-33.47%
19.38
9.366
9.442
81.55%
-14.51%
160.36%

What the Analysts think about PRCT

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
15.16% upside
High $65.00
Low $53.00
$50.86
Current price
$58.57
Average price target

PRCT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-63.21% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$43.5M
23.93%
Net income
$-27.5M
11.79%
Profit margin
-63.21%
-9.8%

PRCT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 23.04%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.63
-$0.56
-$0.51
-$0.54
-
Expected
-$0.58
-$0.57
-$0.51
-$0.44
-$0.56
Surprise
8.35%
-1.97%
-0.86%
23.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for PROCEPT BioRobotics stock?

PROCEPT BioRobotics (PRCT) has a market cap of $2.64B as of April 19, 2024.

What is the P/E ratio for PROCEPT BioRobotics stock?

The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of April 19, 2024.

Does PROCEPT BioRobotics stock pay dividends?

No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next PROCEPT BioRobotics dividend payment date?

PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.

What is the beta indicator for PROCEPT BioRobotics?

PROCEPT BioRobotics (PRCT) does not currently have a Beta indicator.

What is the PROCEPT BioRobotics stock price target?

The target price for PROCEPT BioRobotics (PRCT) stock is $58.57, which is 15.16% above the current price of $50.86. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PROCEPT BioRobotics stock

Buy or sell PROCEPT BioRobotics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing